Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2016 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
Seattle Genetics, Inc.
University of Rochester
City of Hope Medical Center
Stanford University
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01868451
First received: May 30, 2013
Last updated: December 14, 2016
Last verified: December 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2017
  Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)